EMvision Medical Devices Ltd. (AU:EMV) has released an update.
EMVision Medical Devices Ltd has announced impressive results from its groundbreaking neurodiagnostic technology designed to identify strokes and their types early. The EMView study, involving 307 participants, showed high sensitivity and specificity in detecting hemorrhagic and ischemic strokes, paving the way for a validation trial aimed at FDA clearance and commercialization. The trial is expected to cost $4 million and take 6-12 months, backed by the company’s cash reserves.
For further insights into AU:EMV stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Adobe Shares (NASDAQ:ADBE) Jump as Company Embraces AI
- Ford Stock (NYSE:F) Falls as Analysts Turn on It
- Intel’s (NASDAQ:INTC) Foundry Flounders as It Outsources More Chips
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
